Literatur
- 1 Thürlimann B, Keshaviah A, Mouridsen H, Mauriac L, Forbes J F, Paridaens R, Castiglione-Gertsch M,
Gelber R D, Smith I, Goldhirsch A. BIG 1-98: Randomized double-blind phase III study
to evaluate letrozole vs. Tamoxifen as adjuvant endocrine therapy for postmenopausal
women with receptor-positive breast cancer. Proc ASCO 2005, abstr. 511
- 2 Goldstein L, O'Neill A, Sparano J, Perez E, Shulman L, Martino S, Davidson N. E2197:
Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the
adjuvant treatment of node positive and high risk node negative breast cancer. Proc
ASCO 2005, abstr. 512
- 3 Wapnir I, Anderson S, Mamounas S, Geyer C, Hyeon-Jeong J, Constantino J, Fisher B,
Wolmark N. Survival after IBTR in NSABP node negative protocols B-13, B-14, B-19,
B-20 and B-23. Proc ASCO 2005, abstr. 517
- 4
Fisher B, Wickerham D L, Deutsch M, Anderson S, Redmond C, Fisher E R.
Breast tumor recurrence following lumpectomy with and without breast irradiation:
an overview of recent NSABP findings.
Semin Surg Oncol.
1992;
8
153-160
- 5 Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A. et al .European
Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression
from adding pacalitaxel to doxorubicin followed by cyclophosphamide, methotrexate
and fluorouracil. Proc ASCO 2005, abstr. 513
- 6 Gennari A, Conte P, Nanni O, Manzione L, Cortesi E, Boni C. et al .Multicenter randomized
trial of paclitaxel maintenance chemotherapy versus control in metastatic breast cancer
patients achieving a response or stable disease to first-line chemotherapy includine
anthracyclines and paclitaxel: final results from the italian MANTA study. Proc ASCO
2005, abstr. 522
- 7 Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Lluch A. et al .Gemcitabine
plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic
breast cancer patients: results of a European phase III study. Proc ASCO 2005, abstr.
581
- 8 Baxter N N, Virnig B A, Durham S B, Tuttle T M. Radiation after lumpectomy for DCIS
to reduce the risk of invasive breast cancer: A population-based study. Proc ASCO
2005, abstr. 516
- 9 Harbeck N, Bohlmann I, Ross J S, Gruetzmann R, Kristiansen G, Margossian A, Hartmann A,
Cufer T, Paradiso A, Maier S,. EpiBreast Group .Multicenter study validates PITX2
DNA methylation for risk prediction in tamoxifen-treated, node-negative breast cancer
using paraffin-embedded tumor tissue. Proc ASCO 2005, abstr. 505
- 10 Sotiriou C, Wirapati P, Loi S, Desmedt C, Harris A L, Bergh J, Smeds J, Cardoso F,
Delorenzi M, Piccart M. Molecular characterization of clinical grade in breast cancer
(BC) challenges the existence of “grade 2” tumors. Proc ASCO 2005, abstr. 506
- 11 Porter P L, Barlow W, Yeh I -T, Lin M G, Yuan X, Ingle J N, Shapiro C L, Sledge G P,
Livingston R B, Hayes D F. Prognostic value of cell cycle regulators p27 and cyclin
E: Tissue microarray analysis of 1 753 women enrolled in SWOG breast cancer trial
9313. Proc ASCO 2005, abstr. 507
Dr. med. Achim Rody
Zentrum für Gynäkologie und Geburtshilfe · J.-W.-Goethe-Universität Frankfurt
Theodor-Stern-Kai 7
60590 Frankfurt/Main
Phone: 0 69/63 01 51 15
Fax: 0 69/63 01 62 17
Email: achim.rody@em.uni-frankfurt.de
